This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
J.P. Morgan Sticks to Their Hold Rating for Novo Nordisk (0QIU)
J.P. Morgan analyst Richard Vosser maintained a Hold rating on Novo Nordisk today and set a price target of DKK250.00.
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
According to TipRanks, Vosser is ranked #4452 out of 12231 analysts.
In a report released on June 4, Goldman Sachs also maintained a Hold rating on the stock with a DKK305.00 price target.
The company has a one-year high of DKK533.40 and a one-year low of DKK224.25. Currently, Novo Nordisk has an average volume of 6.16M.
Read More on GB:0QIU:
Disclaimer & DisclosureReport an Issue
- Novo Nordisk announces Reimagine 1-3 trials each met primary endpoint
- Novo Nordisk announces new evidence in adults with T2D treated with semaglutide
- Novo Nordisk to present new data on Wegovy across cardiometabolic conditions
- Veru pact with Novo ‘significant event,’ says Canaccord
- Veru announces clinical supply agreement with Novo Nordisk
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
